pirenzepine has been researched along with Hypertrophy in 1 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Hypertrophy: General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy of the M1-selective muscarinic antagonist, pirenzepine, in preventing experimentally induced myopia in a mammalian model, the tree shrew." | 7.69 | The M1 muscarinic antagonist pirenzepine reduces myopia and eye enlargement in the tree shrew. ( Cottriall, CL; McBrien, NA, 1996) |
| "To determine the efficacy of the M1-selective muscarinic antagonist, pirenzepine, in preventing experimentally induced myopia in a mammalian model, the tree shrew." | 3.69 | The M1 muscarinic antagonist pirenzepine reduces myopia and eye enlargement in the tree shrew. ( Cottriall, CL; McBrien, NA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cottriall, CL | 1 |
| McBrien, NA | 1 |
1 other study available for pirenzepine and Hypertrophy
| Article | Year |
|---|---|
The M1 muscarinic antagonist pirenzepine reduces myopia and eye enlargement in the tree shrew.
Topics: Accommodation, Ocular; Animals; Conjunctiva; Disease Models, Animal; Eye; Hypertrophy; Injections; M | 1996 |